Emmaus shareholders approve reverse split authorization and 2021 stock plan

Emmaus Life Sciences, Inc.

Reverse stock split authorization approved: 29,399,449 for, 540,130 against, 90,183 withheld.
2021 Stock Incentive Plan approved: 25,609,777 for, 433,820 against, 36,796 withheld.
Seven directors elected: Yutaka Niihara, Willis C. Lee, Robert Dickey IV, Masaharu Osato, Jane Pine Wood, Wei Peu Zen, Alfred Lui.
Advisory say-on-pay vote approved: 25,543,032 for, 497,065 against; board set frequency at every three years.
Baker Tilly US, LLP ratified as independent auditor for FY2021: 29,935,626 for, 44,800 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.